Zhongnan Medical Journal Press

Home Results

A total of 13 result was found. Results that relate to Cost-utility

Pharmacoeconomic evaluation of Huangkui capsule versus losartan potassium tablets in the treatment of IgA nephropathy

Published on Chinese Journal of Pharmacoepidemiology 2023,32(1):02-09.
9977 times 4034 times

Liang-Wen GOU Zhao-Ting GUO Qiong LUO Nan YANG Ming HU

Huangkui capsule Losartan potassium tablets Chronic kidney disease Pharmacoeconomics Cost-utility analysis
Details
Cost-utility analysis of Shenling Baizhu powder in treatment of sarcopenia in older men

Published on Chinese Journal of Pharmacoepidemiology 2023,32(4):376-383.
8860 times 1806 times

Huan-Huan JIANG Hui-Qin SHEN Zhi-Xiu WANG Yun-Fei CHEN Hui GUO Na XU

Shenling Baizhu powder Sarcopenia Cost-utility analysis Pharmacoeco-nomics
Details
Cost-utility analysis of sacubitril/valsartan, dapagliflozin and empagliflozin in heart failure with reduced ejection fraction

Published on Chinese Journal of Pharmacoepidemiology 2023,32(8):878-885.
8825 times 1859 times

Dan-Dan LU Sheng-Xiang WANG Shan LU Dan PAN Li-Yuan SHI Fei-Chuang Jing2

Heart failure with reduced ejection fraction Sacubitril/valsartan Dapagliflozin Empagliflozin Markov model Cost-utility analysis
Details
Cost-utility analysis of budesonide/formoterol powder inhalation versus salmeterol/fluticasone powder inhalation for asthma in adolescents

Published on Chinese Journal of Pharmacoepidemiology 2024,33(1):60-67.
8931 times 1806 times

SHEN Anle WU Bin LIU Dan JIANG Yuelian WU Juan YIN Yong ZHANG Shunguo

Budesonide/formoterol Salmeterol/fluticasone Cost-utility analysis Asthma Adolescent
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome

Published on Chinese Journal of Pharmacoepidemiology 2023,32(12):1371-1379.
9347 times 1982 times

La-Ji DANZENG Yong-Gong YANG Si-Liang WANG Meng-Ying LIU

Azacitidine Decitabine Myelodysplastic syndrome Markov model Cost-utility analysis Pharmacoeconomics
Details
Pharmacoeconomic evaluation of different doses of rivaroxaban for the prevention of thrombosis in patients with nonvalvular atrial fibrillation

Published on Frontiers in Pharmaceutical Sciences 2023,36(11):233-240.
7274 times 1773 times

Wei LUO Xue-Ying PENG Dong YANG Xin-Mei WU

Nonvalvular atrial fibrillation Rivaroxaban Dose selection Markov model Cost-utility analysis
Details
Cost-utility analysis of edaravone dexborneol for acute ischemic stroke

Published on Chinese Journal of Pharmacoepidemiology 2024,33(1):68-74.
9789 times 3041 times

ZHOU Shasha CHEN Xiangfan CHEN Xia

Edaravone dexborneol Edaravone Acute ischemic stroke Decision tree model Cost-utility analysis
Details
Pharmacoeconomic evaluation of glucagon-like peptide-1 receptor agonist combined with metformin in the treatment of type 2 diabetes mellitus

Published on Chinese Journal of Pharmacoepidemiology 2024,33(4):388-401.
11155 times 2611 times

YU Tian LIU Shaohua WEI Anhua GUO Jieru ZHANG Chengliang LIU Dong LIU Zhelong

Glucagon-like peptide-1 receptor agonist Metformin Type 2 diabetes mellitus Cost-utility Markov model Pharmacoeconomics
Details
Pharmacoeconomic evaluation of fluticasone furoate/umeclidinium/ vilanterol powder for inhalation for the treatment of chronic obstructive pulmonary disease

Published on Chinese Journal of Pharmacoepidemiology 2024,33(7):721-730.
10841 times 2051 times

DING Xueru LIU Huimin HE Xiaodong LI Hua LI Zhihao

Fluticasone furoate/umeclidinium/vilanterol Chronic obstructive pulmonary disease Markov model Cost-utility analysis Pharmacoeconomic
Details
Cost-utility analysis of pembrolizumab combined with chemotherapy for advanced malignant pleural mesothelioma

Published on Chinese Journal of Pharmacoepidemiology 2024,33(10):1107-1114.
10359 times 2027 times

HU Yunjia ZOU Keqing HOU Yanhong

Pembrolizumab Chemotherapy Advanced malignant pleural mesothelioma Partitioned survival model Cost-utility analysis Pharmacoeconomic evaluation
Details
Pharmacoeconomic evaluation of third-line treatment of advanced non-small cell lung cancer with anlotinib

Published on Frontiers in Pharmaceutical Sciences 2024,28(4):639-647.
11913 times 1381 times

YUAN Wenjie KANG Shuo WANG Xiaohui GONG Yuan PAN Zhenhua

Anlotinib Pharmacoeconomics Non-small cell lung cancer Cost-utility analysis
Details
Cost-utility analysis of albumin paclitaxel combined with atezolizumab for the treatment of PD-L1-positive advanced triple-negative breast cancer

Published on Frontiers in Pharmaceutical Sciences 2025,29(7):1179-1185.
8841 times 1156 times

HU Xiuping TAN Lunan LI Hongbo YAO Huitao

Albumin paclitaxel Atezolizumab Pharmacoeconomics Cost-utility analysis
Details
Cost-utility analysis of injectable copanlisib in combination with rituximab for the treatment of relapsed and refractory non-Hodgkin lymphoma

Published on Frontiers in Pharmaceutical Sciences 2025,29(10):1717-1723.
4358 times 707 times

WU Yongwei XIE Xinyu

Copanlisib Rituximab Non-Hodgkin lymphoma Cost-utility analysis
Details